Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03034928 · ClinicalTrials.gov registry record · NA
Clinical Biocompatibility Evaluation of Contact Lens Coatings
A NA study, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT03034928: Completed NA study, sponsored by Alcon Research.
NCT03034928 is a NA study that has completed, run by Alcon Research. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03034928, a NA study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective is to evaluate corneal staining observed after 2 hours of wear with contact lenses with investigational coating against PureVision™ lenses, all pre-cycled with OPTI-FREE® RepleniSH® multi-purpose disinfection solution.
Primary Outcome
Percent of solution-related corneal staining area was assessed first in each of the 5 corneal regions: central, superior, nasal, inferior, and temporal. The average of corneal staining area was then calculated as the average over all 5 regions. A higher percentage reflects more damage to the corneal surface. Both eyes contributed to the analysis. No hypotheses were formulated; no inferences were made and only descriptive statistics were used in the reporting.
Interventions
- DEVICE Contact lens with investigational coating 1
- DEVICE Balafilcon A contact lens
- DEVICE OPTI-FREE® RepleniSH® MPDS
- DEVICE Contact lens with investigational coating 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2017-03-14 |
| Phase | NA |
What the finished NCT03034928 record still lists
NCT03034928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Contact lens with investigational coating 1 is the first listed.
NCT03034928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03034928 about?
NCT03034928 is a clinical study titled "Clinical Biocompatibility Evaluation of Contact Lens Coatings". The primary objective is to evaluate corneal staining observed after 2 hours of wear with contact lenses with investigational coating against PureVision™ lenses, all pre-cycled with OPTI-FREE® RepleniSH® multi-purpose disinfection solution.
What is the current status of trial NCT03034928?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2017-02-14. Estimated completion is 2017-03-14.
What interventions are being tested in trial NCT03034928?
The interventions under investigation include: Contact lens with investigational coating 1 (DEVICE), Balafilcon A contact lens (DEVICE), OPTI-FREE® RepleniSH® MPDS (DEVICE), Contact lens with investigational coating 2 (DEVICE).
Who is sponsoring clinical trial NCT03034928?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03034928's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI